Clinical Trial Update: Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations [Phase 3]

View source ↗

Summary

Phase 3 trial of oral infigratinib as adjuvant treatment for invasive urothelial carcinoma with FGFR3 alterations has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma
• Urothelial Bladder Cancer

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-03-13